<DOC>
	<DOCNO>NCT02508389</DOCNO>
	<brief_summary>The purpose phase 2 , GT-201 clinical study determine GC4419 administer prior intensity-modulated radiation therapy ( IMRT ) reduce incidence , duration , severity radiation induce oral mucositis patient diagnose locally advanced , non-metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>A Study Effects GC4419 Radiation Induced Oral Mucositis Patients With Head/Neck Cancer</brief_title>
	<detailed_description>GT-201 randomize , double-blind , placebo-controlled , multi-center study conduct U.S. evaluate GC4419 administer IV reduction incidence , duration , severity radiation induce oral mucositis patient receive cisplatin plus intensity-modulated radiation therapy post-operative , definitive treatment locally advance , non-metastatic squamous cell carcinoma head neck , limited oral cavity oropharynx . Patients randomize equally 1 3 treatment arm : Arm A : 30 mg GC4419 per day ( 60 min IV infusion complete within 60 minute prior IMRT ) , concurrent daily fraction IMRT ( 2.0 - 2.2 Gy ) total 60 - 72 Gy approximately 7 week , plus cisplatin administer 80 - 100 mg/m2 every three week 3 dos 30 - 40 mg/m2 weekly 6-7 dos ( investigator 's choice ) . Arm B : 90 mg GC4419 per day ( 60 min IV infusion complete within 60 minute prior IMRT ) , concurrent daily fraction IMRT ( 2.0 - 2.2 Gy ) total 60 - 72 Gy approximately 7 week , plus cisplatin administer 80 - 100 mg/m2 every three week 3 dos 30 - 40 mg/m2 weekly 6-7 dos ( investigator 's choice ) . Arm C : Placebo daily ( 60 min IV infusion complete within 60 minute prior IMRT ) , concurrent daily fraction IMRT ( 2.0 - 2.2 Gy ) total 60 - 72 Gy approximately 7 week , plus cisplatin administer 80 - 100 mg/m2 every three week 3 dos 30 - 40 mg/m2 weekly 6-7 dos ( investigator 's choice ) . Planned radiation field 3 arm must include least two oral site ( buccal mucosa , floor mouth , tongue , soft palate ) site receive dose least 50 Gy . All patient assess twice weekly oral mucositis per WHO grade criterion completion IMRT , weekly thereafter ( necessary ) 8 week , oral mucositis resolve ≤ Grade 1 . Approximately 200 total ensure roughly 60 patient per arm receive study drug complete requirement primary endpoint analysis , define patient receive minimum cumulative dose 60 Gy .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>1 . Pathologicallyconfirmed diagnosis squamous cell carcinoma head neck , define SCC oral cavity oropharynx treat cisplatin plus concurrent IMRT Note : Patients unknown primary tumor whose treatment plan match requirement specify Inclusion Criteria # 2 # 3 eligible trial . 2 . Treatment plan receive continuous course IMRT deliver single daily fraction 2.0 2.2 Gy cumulative radiation dose 60 Gy 72 Gy . Planned radiation treatment field must include least two oral site ( buccal mucosa , floor mouth , tongue , soft palate ) plan receive total &gt; 50 Gy . Patients prior surgery eligible , provide fully recover surgery , patient may surgery future eligible . 3 . Treatment plan receive standard cisplatin monotherapy administer either every three week ( 80100 mg/m2 3 dos ) weekly ( 3040 mg/m2 67 dos ) . The decision chemotherapy regimen use combination IMRT GC4419 discretion investigator . 4 . Age 18 year old 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 6 . Adequate hematologic function indicate : Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Hemoglobin ( Hgb ) ≥ 9.0 g/dL Platelet count ≥ 100,000/mm3 7 . Adequate renal liver function indicate : Serum creatinine acceptable treatment cisplatin per institutional guideline Total bilirubin ≤ 1.5 x uppernormal limit ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN 8 . Human papilloma virus ( HPV ) status tumor document use tumor immunohistochemistry HPVp16 accept test 9 . Serum pregnancy test negative female childbearing potential 10 . Males female must agree use effective contraception start prior first day treatment continue 30 day last dose GC4419 11 . Properly obtain write informed consent 1 . Tumor lip , larynx , hypopharynx , nasopharynx , sinus , salivary gland 2 . Metastatic disease ( Stage IV C ) 3 . Prior radiotherapy region study cancer adjacent anatomical site 25 % total body marrowbearing area ( potentially interfere chemotolerance ) 4 . Prior induction chemotherapy 5 . Receiving approve investigational anticancer agent provide study 6 . Participation another clinical trial use another investigational agent within 30 day study entry 7 . Requirement significantly modify diet ( liquids and/or solid ) due compromise oral/pharyngeal function baseline 8 . Requirement baseline parenteral gastrointestinal tubedelivered nutrition reason 9 . Malignant tumor HNC within last 5 year , unless treat definitively low risk recurrence judgment treat investigator 10 . Active infectious disease exclude oral candidiasis 11 . Presence oral mucositis ( WHO Score ≥ Grade 1 ) study entry 12 . Known history HIV active hepatitis B/C ( patient vaccinate hepatitis B history infection eligible ) 13 . Female patient pregnant breastfeed 14 . Known allergy intolerance cisplatin similar platinumcontaining compound 15 . Requirement concurrent treatment nitrate drug may , judgment treat investigator , create risk precipitous decrease blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>oral cavity</keyword>
	<keyword>oropharynx</keyword>
	<keyword>intensity-modulated radiation therapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>oral mucositis</keyword>
	<keyword>superoxide dismutase</keyword>
	<keyword>radioprotection</keyword>
</DOC>